ZK-283197
From Wikipedia, the free encyclopedia
Jump to navigation
Jump to search
| Clinical data | |
|---|---|
| Other names | BAY 86-5310; SH-T04211C |
| Routes of administration | By mouth[1] |
| Drug class | Estrogen; Selective ERβ agonist |
| Identifiers | |
| CAS Number | |
ZK-283197 (also known as BAY 86-5310 or SH-T04211C) is a selective and orally active ERβ agonist which was under development by Bayer Healthcare AG for the treatment of vasomotor symptoms.[1][2] It reached phase II clinical trials prior to the discontinuation of its development.[1] Its development was terminated in 2014.[1]
References[edit]
- ^ a b c d "ZK 283197 - AdisInsight". adisinsight.springer.com.
- ^ US 332204, Pietras, R. J., & Jung, M. E., "Methods of using estrogen receptor-beta ligands as radiation mitigators", published 2015-01-15
This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it. |
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
Hidden categories:
- Infobox drug articles without a structure image
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- All stub articles